Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori [Efficacia e sicurezza della somministrazione di PYLERA` (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell'Helicobacter pylori].

Trial Profile

Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori [Efficacia e sicurezza della somministrazione di PYLERA` (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell'Helicobacter pylori].

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2013

At a glance

  • Drugs Tripotassium dicitrato bismuthate/tetracycline/metronidazole (Primary) ; Omeprazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Sponsors Adare Pharmaceuticals
  • Most Recent Events

    • 19 May 2012 Planned number of patients changed from 12 to 50 as reported by European Clinical Trials Database.
    • 19 May 2012 Company added in association field as reported by European Clinical Trials Database.
    • 19 May 2012 Additional trial locations added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top